Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
作者： Helena Linardou , Issa J. Dahabreh , Dimitrios Bafaloukos , Paris Kosmidis , Samuel Murray
DOI: 10.1038/NRCLINONC.2009.62
关键词: Monoclonal antibody 、 Somatic cell 、 Medicine 、 Carcinoma 、 Internal medicine 、 Adenocarcinoma 、 Lung cancer 、 Tyrosine kinase 、 KRAS 、 Oncology 、 Colorectal cancer
摘要: … the predictive and prognostic value of EGFR mutational status and other candidate biomarkers. … of anti-EGFR therapy in NSCLC, focusing on the influence of somatic EGFR mutations on …
core.ac.uk
nature.com
sci-hub.se 参考文章(112)
L. Paz-Ares, J. M. Sanchez, A. García-Velasco, B. Massuti, G. López-Vivanco, M. Provencio, A. Montes, D. Isla, M. L. Amador, R. Rosell, A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) Journal of Clinical Oncology. ,vol. 24, pp. 7020- 7020 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.7020
Assessing EGFR mutations. The New England Journal of Medicine. ,vol. 354, pp. 526- ,(2006) , 10.1056/NEJMC052564
Shinichi Toyooka, Katsuyuki Kiura, Tetsuya Mitsudomi, None, EGFR mutation and response of lung cancer to gefitinib. The New England Journal of Medicine. ,vol. 352, pp. 2136- ,(2005) , 10.1056/NEJM200505193522019
Allan R. Li, Dhananjay Chitale, Gregory J. Riely, William Pao, Vincent A. Miller, Maureen F. Zakowski, Valerie Rusch, Mark G. Kris, Marc Ladanyi, EGFR Mutations in Lung Adenocarcinomas: Clinical Testing Experience and Relationship to EGFR Gene Copy Number and Immunohistochemical Expression The Journal of Molecular Diagnostics. ,vol. 10, pp. 242- 248 ,(2008) , 10.2353/JMOLDX.2008.070178
Roy S. Herbst, Masahiro Fukuoka, José Baselga, Gefitinib — a novel targeted approach to treating cancer Nature Reviews Cancer. ,vol. 4, pp. 956- 965 ,(2004) , 10.1038/NRC1506
Yosef Yarden, Mark X. Sliwkowski, Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. ,vol. 2, pp. 127- 137 ,(2001) , 10.1038/35052073
Sreenath V. Sharma, Daphne W. Bell, Jeffrey Settleman, Daniel A. Haber, Epidermal growth factor receptor mutations in lung cancer Nature Reviews Cancer. ,vol. 7, pp. 169- 181 ,(2007) , 10.1038/NRC2088
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, Chang-Qi Zhu, Suzanne Kamel-Reid, Jeremy Squire, Ian Lorimer, Tong Zhang, Ni Liu, Manijeh Daneshmand, Paula Marrano, Gilda da Cunha Santos, Alain Lagarde, Frank Richardson, Lesley Seymour, Marlo Whitehead, Keyue Ding, Joseph Pater, Frances A. Shepherd, Erlotinib in lung cancer - molecular and clinical predictors of outcome. The New England Journal of Medicine. ,vol. 353, pp. 133- 144 ,(2005) , 10.1056/NEJMOA050736
Pasi A. Jänne, Sarada Gurubhagavatula, Beow Y. Yeap, Joan Lucca, Patricia Ostler, Arthur T. Skarin, Panos Fidias, Thomas J. Lynch, Bruce E. Johnson, Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access study Lung Cancer. ,vol. 44, pp. 221- 230 ,(2004) , 10.1016/J.LUNGCAN.2003.12.014
A G Pallis, A Voutsina, Ar Kalikaki, J Souglakos, E Briasoulis, S Murray, A Koutsopoulos, M Tripaki, E Stathopoulos, D Mavroudis, V Georgoulias, ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer British Journal of Cancer. ,vol. 97, pp. 1560- 1566 ,(2007) , 10.1038/SJ.BJC.6604068